Similar Papers

Paper Title
Journal
Date
Author
Upfront Autologous Hematopoietic Stem-Cell Transplantation Improves Overall Survival in Comparison with Bortezomib-Based Intensification Therapy in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the Randomized Phase 3 EMN02/HO95 Study
...
Blood | VOL. 136
, et. al. ...
05 Nov 2020
Worldwide Examination of Patients with CLL Hospitalized for COVID-19
...
Blood | VOL. 136
, et. al. ...
05 Nov 2020
Safety and Efficacy from a Phase 1b/2 Study of IMGN632 in Combination with Azacitidine and Venetoclax for Patients with CD123-Positive Acute Myeloid Leukemia
Naval Daver ...
Blood | VOL. 138
Naval Daver, et. al.Naval Daver ...
05 Nov 2021
Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update
Cesar Rodriguez ...
Blood | VOL. 134
Cesar Rodriguez, et. al.Cesar Rodriguez ...
13 Nov 2019
View more papers

More From: Blood

Paper Title
Journal
Date
Author
The JAK2 46/1 haplotype influences PD-L1 expression.
Gonzalo Carreño-Tarragona ... Miguel Manzanares
Blood | VOL. -
Gonzalo Carreño-Tarragona, et. al.Gonzalo Carreño-Tarragona ... Miguel Manzanares
07 Feb 2025
Targeting cell surface VISTA expression on allospecific naïve T cells promotes tolerance.
Brent H Koehn ... Bruce R Blazar
Blood | VOL. -
Brent H Koehn, et. al.Brent H Koehn ... Bruce R Blazar
07 Feb 2025
Venetoclax plus Daunorubicin and Cytarabine for Newly Diagnosed Acute Myeloid Leukemia: Results of a Phase 1b Study.
Ioannis Mantzaris ... Eric J Feldman
Blood | VOL. -
Ioannis Mantzaris, et. al.Ioannis Mantzaris ... Eric J Feldman
07 Feb 2025
Acute myeloid leukemia with BCL6 and KMT2A dual rearrangements.
Qiudan Shen ... Shimin Hu
Blood | VOL. 145
Qiudan Shen, et. al.Qiudan Shen ... Shimin Hu
06 Feb 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.